Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2-Reference-Cited by-同舟云学术

Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2

Published:2016-06-08 Issue:8 Volume:65 Page:941-949
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Stenehjem David D.,Toole Michael,Merriman Joseph,Parikh Kinjal,Daignault Stephanie,Scarlett Sarah,Esper Peg,Skinner Katherine,Udager Aaron,Tantravahi Srinivas Kiran,Gill David,Straubhar Alli M.,Agarwal Archana M.,Grossmann Kenneth F.,Samlowski Wolfram E.,Redman Bruce,Agarwal Neeraj,Alva Ajjai

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-016-1854-1.pdf

Reference30 articles.

1. Hudes GR, Carducci MA, Choueiri TK et al (2011) NCCN Task force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Cancer Netw 9(Suppl 1):S1–S29

2. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124. doi: 10.1056/NEJMoa065044

3. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281. doi: 10.1056/NEJMoa066838

4. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068. doi: 10.1200/JCO.2009.23.9764

5. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111. doi: 10.1016/S0140-6736(07)61904-7

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-2 based cancer immunotherapies: an evolving paradigm;Frontiers in Immunology;2024-07-24

2. Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study;Diagnostics;2022-05-30

3. Interleukin-2 therapy of cancer-clinical perspectives;International Immunopharmacology;2021-09

4. Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2;Journal of Investigative Medicine;2021-02-04

5. Landscape of Immunotherapy in Genitourinary Malignancies;Advances in Experimental Medicine and Biology;2021